31 results about "Dicalcium phosphate dihydrate" patented technology

a biocompatible and biodegradable implant for a cavity in a bone of a living organism is made of a biocompatible and biodegradable granules which are selected from the group including biopolymers, bioglasses, bioceramics preferably calcium sulfate, calcium phosphate such as monocalcium phosphate monohydrate, monocalcium phosphate anhydrous, dicalcium phosphate dihydrate, dicalcium phosphate anhydrous, tetracalcium phosphate, calcium orthophosphate phosphate, α-tricalcium phosphate, β-tricalcium phosphate, apatite such as hydroxyapatite, or a mixture thereof. The biocompatible and biodegradable granules are provided with a coating, which comprises at least one layer of a biocompatible and biodegradable polymer which is selected from the group including poly((α-hydroxyesters), poly(orthoesters), polyanhydrides, poly(phosphazenes), poly(propylene fumarate), poly(ester amides), poly(ethylene fumarate), polylactide, polyglycolide, polycaprolactone, poly(glycolide-co-trimethylene carbonate), polydioxanone, co-polymers thereof and blends of those polymers. The biocompatible and biodegradable implants are obtained by fusing together the polymer-coated granules through polymer-linkage of the polymer coatings of neighboring granules.

A dentinal tubule sealant comprises poorly-soluble calcium phosphate particles (A), a phosphorus-free calcium compound (B), and water (C), wherein the particles (A) are at least one member selected from the group consisting of dicalcium phosphate anhydrous [CaHPO4] particles, α-tricalcium phosphate [α-Ca3(PO4)2] particles, β-tricalcium phosphate [β-Ca3(PO4)2] particles, amorphous calcium phosphate [Ca3(PO4)2.nH2O] particles, calcium pyrophosphate [Ca2P2O7] particles, calcium pyrophosphate dihydrate [Ca2P2O7.2H2O] particles, octacalcium phosphate pentahydrate [Ca8H2(PO4)6.5H2O] particles, and dicalcium phosphate dihydrate [CaHPO4.2H2O] particles, and the dentinal tubule sealant contains 30 to 76% by weight of the particles (A), 0.001 to 4% by weight of the compound (B), and 23 to 69% by weight of the water (C). Thus, there is provided a dentinal tubule sealant capable of sealing dentinal tubules of an exposed dentin and also remineralizing the surrounding dentin after the sealing.

This invention provides a method for stabilization and treatment of heavy metal bearing materials and wastes subject to acid leaching tests or leach conditions and odor limits by addition of acid semi-soluble DiCalcium Phosphate DiHydrate such that the leaching potential is inhibited to desired levels and odors are reduced to desired levels and the material or waste is free flowing, more permeable, less weight and permits immediate handling and disposal or reuse. The resultant material or waste after stabilization is deemed suitable for on-site reuse, off-site reuse or disposal as RCRA non-hazardous waste.

This invention provides a method for stabilization and treatment of heavy metal bearing materials and wastes subject to acid leaching tests or leach conditions and odor limits by addition of acid semi-soluble pulverized or fine particle DiCalcium Phosphate DiHydrate such that the leaching potential is inhibited to desired levels and odors are reduced to desired levels and the material or waste is free flowing, more permeable, less weight and permits immediate handling and disposal or reuse. The resultant material or waste after stabilization is deemed suitable for on-site reuse, off-site reuse or disposal as RCRA non-hazardous waste.

The present invention relates to a flat bread dough composition, comprising: A) flour; B) shortening; C) water; and D) a leavening system having a leavening base and a leavening acid having a combination selected from the group consisting of a) sodium aluminum phosphate and dicalcium phosphate dihydrate; b) sodium aluminum phosphate and sodium acid pyrophosphate; c) sodium acid pyrophosphate and dicalcium phosphate dihydrate; d) sodium acid pyrophosphate, monocalcium phosphate, and calcium acid pyrophosphate; e) dicalcium phosphate dehydrate, monocalcium phosphate, and calcium acid pyrophosphate; f) sodium aluminum phosphate, sodium acid pyrophosphate, and dicalcium phosphate dihydrate; g) sodium aluminum sulfate and dicalcium phosphate dihydrate; and h) sodium aluminum sulfate and sodium acid pyrophosphate, the sodium acid pyrophosphate exhibiting an evolved percentage of carbon dioxide of about 30 or less at room temperature prior to baking, and the slower reacting of the leavening acids in the combination being at least 10 wt % of the total weight of the acid combination.

The invention provides a hydroxyapatite coating with biological activity and a hierarchical structure on the surface of a degradable magnesium-based endosteal implant and a preparation method. The coating comprises an inner fluorinated film and an outer hydroxyapatite conversion coating. The method comprises the following steps of: soaking magnesium and magnesium alloy in hydrofluoric acid to generate a chemical conversion film MgF2, soaking the chemical conversion film MgF2 in solution containing calcium phosphate, and generating a dicalcium phosphate dihydrate coating by a chemical deposition method; and finally, converting the dicalcium phosphate dihydrate coating into a thick hydroxyapatite coating with a micro-nano hierarchical structure and a composite surface appearance in situ under high temperature and pressure by a hydrothermal conversion method. The hydroxyapatite coating has high bonding strength with magnesium and magnesium alloy matrixes, and the corrosion resistance andbiological activity of the magnesium matrixes are obviously improved. The preparation method is simple, convenient and feasible, has low cost, and can be applied to magnesium-based endosteal implant devices with any complex shapes.

The invention relates to bone cement as well as a preparation method and application thereof. The bone cement is prepared from 50 to 92 weight percent of alpha-tricalcium phosphate, 3 to 10 weight percent of dicalcium phosphate dihydrate, 2 to 30 weight percent of starch and 0.5 to 15 weight percent of nano-silver loaded diatomite. The bone cement disclosed by the invention has the advantages of injection, antibacterial property and degradability, and can be used for treating vertebral compression fracture caused by osteoporosis induced by glucocorticoid.

The invention relates to a preparation method of calcium phosphate-coated magnesium powder. According to the method, a deposition solution prepared from calcium nitrate, monopotassium phosphate and disodium ethylene diamine tetraacetic acid in a certain ratio is used, and gas-atomized pure magnesium powder is used for a deposition reaction under the deposition conditions that the pH value ranges from 3.6 to 4.8, the deposition temperature ranges from 10 DEG C to 20 DEG C and the stirring speed ranges from 200 rpm to 400 rpm. With the preparation method, a complete and uniform coating layer is prepared on the surface of the pure magnesium powder, the main phase of the coating layer is dicalcium phosphate dihydrate and a small amount of magnesium hydrogen phosphate, and the corrosion resistance of the magnesium powder in a chlorine-containing environment can be improved.

This invention provides a method for stabilization of heavy metal bearing materials and wastes subject to acid leaching tests or leach conditions by addition of acid semi-soluble DiCalcium Phosphate DiHydrate such that the leaching potential is inhibited to desired levels and the material or waste is free flowing, more permeable, less weight and permits immediate handling and disposal or reuse. The resultant material or waste after stabilization is deemed suitable for on-site reuse, off-site reuse or disposal as RCRA non-hazardous waste.

The present invention discloses a method of manufacturing pure dicalcium phosphate ceramics or dicalcium phosphate / hydroxyapaite (HA) biphasic ceramics for medical applications in hard tissue areas to be used as implant materials. These ceramic implant materials are in granular form or in block form, and are prepared by using an acidic phosphate compound, a basic calcium phosphate compound comprising HA, and water. The dicalcium phosphate ceramic comprises either dicalcium phosphate dihydrate (CaHPO4.2H2O, DCPD) or dicalcium anhydrous (CaHPO4, DCPA). Wherein, when the acidic phosphate compound is provided in an amount stoichiometrically equal to or in excess relative to the basic calcium phosphate compound, a reaction product is the DCPD or DCPA ceramic; when the acidic phosphate compound is provided in the amount stoichiometrically less than the basic calcium phosphate compound, the reaction product is the DCPD / HA or DCPA / HA biphasic ceramic.

The invention belongs to the technical field of medicines, and provides a stable paroxetine hydrochloride tablet and a preparation method thereof. The paroxetine hydrochloride tablet comprises the following components in parts by weight: 7.6 parts of paroxetine hydrochloride, 67.4-81.9 parts of a filler, 2-5 parts of an adhesive, 3-10 parts of a stabilizer, 5-7 parts of a disintegrant and 0.5-3 parts of a lubricant, wherein the stabilizer is sucrose, the filler is calcium hydrogen phosphate dihydrate, the disintegrant is sodium carboxymethyl starch, the adhesive is povidone K30, and the lubricant is magnesium stearate. The preparation method of the paroxetine hydrochloride tablet adopts a wet granulation process. The method solves the problems that paroxetine hydrochloride products turn red in the wet granulation process and the hardness of paroxetine hydrochloride tablets is poor at high temperature when calcium phosphate dihydrate is used as a main filler.

The invention relates to a pharmaceutical composition containing a dexzopiclone tablet, belonging to the technical field of medicine. Commercially available dexzopiclone tablets are of three specifications, i.e., 1 mg, 2 mg and 3 mg. Due to small specifications of the dexzopiclone tablets, content uniformity of prepared tablets can hardly achieve standards; and since the dexzopiclone is hardly soluble in water, reproducibility of the dissolution data of tablets of different batches is poor. The technical scheme of the invention is as follows: the dexzopiclone tablet is characterized by containing, by mass, 1% of dexzopiclone with D90 of below 30 mu m, 0 to 77.5% of dicalcium phosphate dihydrate, 20 to 97.5% of microcrystalline cellulose, 1% of croscarmellose sodium and 0.5% of magnesium stearate. The technical scheme of the invention overcomes the above-mentioned problems in the prior art.

The invention provides a composition for tooth-surface anticaries repair and a preparation method thereof, and relates to a composition. The invention provides the composition taking tetracalciumphosphate and dicalcium phosphate as main raw materials for tooth-surface anticaries repair, and the preparation method thereof. The composition comprises calcification agent powder and solidification liquid, wherein the mass ratio of the calcification agent powder to the solidification liquid is 0.1 to 10; the calcification agent powder comprises tetracalciumphosphate powder and dicalcium phosphate powder; the particle size of the calcification agent powder can be less than or equal to 50 mu m; the dicalcium phosphate can be dicalcium phosphate dihydrate or anhydrous dicalcium phosphate and the like; the solidification liquid may be at least one of water-soluble phosphate solution, citric acid solution, sodium alginate solution and the like; and the pH of the composition for tooth-surface anticaries repair can be 5 to 9. During preparation, the tetracalciumphosphate powder and the dicalcium phosphate powder are mixed and ground to obtain the calcification agent powder; the solidification liquid is prepared; and the calcification agent powder is mixed with the solidification liquid to obtain the composition for tooth-surface anticaries repair.

The invention discloses a benzenesulfonate amlodipine dispersible tablet, which is prepared from the following ingredients in percentage by mass: 3.5% of benzenesulfonate amlodipine, 42-82% of microcrystalline cellulose SH102, 12.5-45% of dicalcium phosphate anhydrous, 1.0-6.0% of carboxymethyl starch sodium and 1.0-3.0% of magnesium stearate. The preparation method comprises the following steps:firstly, adding benzenesulfonate amlodipine, carboxymethyl starch sodium and 1 / 3 of microcrystalline cellulose of a prescription dosage to be mixed for 8-15 minutes, sieving by a sieve of 40 meshes, and adding a residual quantity of microcrystalline cellulose to be mixed for 8-15 minutes; then, adding the dicalcium phosphate anhydrous of the prescription dosage to be mixed for 15-25 minutes, finally, mixing with magnesium stearate for 2-5 minutes, and tableting. The benzenesulfonate amlodipine dispersible tablet provided by the invention has the advantages of the tablet and liquid preparation,is convenient in taking, is quick in disintegration, is quick in absorption and higher in blood pressure reduction effect and is high in bioavailability, blood pressure is more effectively controlled, and the adverse reaction of the medicine can be lowered. A 5-min dissolution rate is as high as 97.8%, and therefore, the benzenesulfonate amlodipine dispersible tablet has the advantages of high accumulated dissolution rate, high bioavailability, good stability, simple preparation technology and the like and is suitable for industrialized production and the like.

The invention discloses a tooth filling composite material and a preparation method thereof. The preparation method comprises the steps that nano silicon powder, ethyl acetate, hydroxy cyclohexyl acetophenone and an acrylate monomer are mixed, after a dispersion medium is steamed out, illumination solidification is conducted, after crushing, a composite filler is obtained, and dicalcium phosphatemonohydrate, anhydrous dicalcium phosphate, dicalcium phosphate dihydrate, calcium phosphate dibasic anhydrous, anhydrous magnesium sulfate, sodium chloride and sodium bicarbonate are mixed and then ground to obtain mixed powder; the mixed powder, solvent, a binding agent, fibrefill, a biological filler and the composite filler are mixed to obtain the tooth filling composite material. The problemsare solved that setting time of traditional filling materials is longer, and the compressive strength of the traditional filling materials is relatively inadequate.

The invention provides an oral bacteriostatic composition. The composition comprises, in parts by weight as follows: 10-30 parts of traditional Chinese medicine extract, 20-30 parts of longan seed powder, 0.1-0.5 parts of sodium saccharin, 15-30 parts of sodium polyoxyethylene lauryl alchohol ether sulfate, 15-30 parts of sodium phytate, 5-10 parts of glucose oxidase, 5-18 parts of dicalcium phosphate dihydrate, 1-8 parts of silica and 2-8 parts of xylitol. The invention provides the oral bacteriostatic composition, which is prepared by a conventional method and capable of effectively inhibiting the growth of harmful bacteria, improving oral microecology, promoting the repair and defense of oral mucous membrane, killing HP and preventing it, the function of treating dental caries, particularly for HP in oral cavity, has a good killing or inhibiting effect. In addition, the composition can also effectively remove internal heat, treat oral ulcer, sore throat, dental calculus and halitosis, and has broad application prospects.

The invention discloses a nefopam hydrochloride tablet and relates to the technical field of pharmaceutical preparation. The nefopam hydrochloride tablet is prepared from the following raw materials in parts by weight: 30-50 parts of dicalcium phosphate dihydrate, 25-50 parts of microcrystalline cellulose, 1-5 parts of hydroxypropyl methylcellulose, 1-8 parts of anhydrous silica gel, 1-6 parts ofmagnesium stearate, 10-38 parts of nefopam hydrochloride and 2-20 parts of white Opadry 20A58806. According to the nefopam hydrochloride tablet, the problems that an existing nefopam hydrochloride tablet is not coated, the quality of the processing process is not well controlled, the produced nefopam hydrochloride tablet is prone to being polluted, and consequently, the drug efficacy is affected are solved.

Brushite (DCPD, dicalcium phosphate dihydrate, CaHPO4-2HH2O) and octacaicium phosphate (OCP, Ca8(HPO4)2(PO4)4-5H2O) granules in the millimetre size range were prepared by using calcium carbonate granules of marble-origin as the starting material. The method of the invention comprised of soaking the marble granules in aqueous solutions containing phosphate and / or calcium ions at temperatures between 20° and 75° C. The load-bearing DCPD and OCP granules of this invention are useful in maxillofacial and orthopedic void / bone defect filiing and grafting applications.